Listed

Organogenesis Holdings Inc.

ORGONasdaqCIK 1661181HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$43.8mRevenue, Q2 FY2026, three months to 2026-06-30$43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$43.8mRevenue, Q2 FY2026, three months to 2026-06-30$43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure−56.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−116.5%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$51.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Revenue: $43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure−104.1 pts on a year earlier
  • Net margin−220.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$96.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Revenue: $43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure−210.7 pts on a year earlier
  • Diluted EPS−$0.77Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure−670.0% on a year earlier
  • Free cash flow−$32.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$31.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338049. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338049. Derived: 6-month figure less the 3-month figure.Report this figure+10.3% on a year earlier

Last eight quarters

Full statements
Revenue$43.8mGross margin not reported
Diluted EPS−$0.77, Q2 FY2026
Free cash flow−$32.8m, Q2 FY2026
Organogenesis Holdings Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m115Revenue, Q3 FY2024, three months to 2024-09-30$115.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure127Revenue, Q4 FY2024, three months to 2024-12-31$126.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure86.7Revenue, Q1 FY2025, three months to 2025-03-31$86.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure101Revenue, Q2 FY2025, three months to 2025-06-30$101.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure151Revenue, Q3 FY2025, three months to 2025-09-30$150.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure226Revenue, Q4 FY2025, three months to 2025-12-31$225.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure37.2Revenue, Q1 FY2026, three months to 2026-03-31$37.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure43.8Revenue, Q2 FY2026, three months to 2026-06-30$43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure
Gross margin%76.7%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $88.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2024-11-12, accession 0000950170-24-125431.Revenue: $115.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure75.5%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $95.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-27, accession 0000950170-25-029137. Derived: 12-month figure less the 9-month figure.Revenue: $126.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure72.6%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $63.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-05-08, accession 0000950170-25-066962.Revenue: $86.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figurenot reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%5.4%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Revenue: $115.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure8.1%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $10.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Revenue: $126.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure(30.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$26.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Revenue: $86.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(12.5%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$12.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Revenue: $101.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure13.7%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $20.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Revenue: $150.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure28.1%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $63.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Revenue: $225.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure(185.1%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$68.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Revenue: $37.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(116.5%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$51.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Revenue: $43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure
Net margin%10.7%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $12.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Revenue: $115.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure6.1%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $7.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Revenue: $126.7m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure(21.7%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$18.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Revenue: $86.7m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(9.3%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Revenue: $101.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure14.3%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $21.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Revenue: $150.9m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figure19.4%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $43.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Revenue: $225.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure(142.8%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$53.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Revenue: $37.2m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(220.0%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$96.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Revenue: $43.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure
Diluted EPS$ per share0.09Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figurenot reported (Diluted EPS not reported)(0.17)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(0.10)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure0.11Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269697.Report this figurenot reported (Diluted EPS not reported)(0.44)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(0.77)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-338049.Report this figure
Free cash flow$m6.1Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269697. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269697. Derived: 9-month figure less the 6-month figure.Report this figure7.6Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $10.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Capital expenditure: $3.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure(23.6)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$19.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Capital expenditure: $3.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(36.5)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$32.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338049. Derived: 6-month figure less the 3-month figure.Capital expenditure: $3.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338049. Derived: 6-month figure less the 3-month figure.Report this figure0.8Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $3.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269697. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269697. Derived: 9-month figure less the 6-month figure.Report this figure34.8Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $39.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Capital expenditure: $4.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076730. Derived: 12-month figure less the 9-month figure.Report this figure18.0Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $21.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Capital expenditure: $3.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001661181-26-000008.Report this figure(32.8)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$31.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-338049. Derived: 6-month figure less the 3-month figure.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-338049. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$564.2mGross margin not reported
Diluted EPS$0.15, FY2025
Free cash flow−$24.5m, FY2025
Organogenesis Holdings Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m467Revenue, FY2021, twelve months to 2021-12-31$467.4m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-29, accession 0000950170-24-023150.Report this figure451Revenue, FY2022, twelve months to 2022-12-31$450.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-27, accession 0000950170-25-029137.Report this figure433Revenue, FY2023, twelve months to 2023-12-31$433.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure482Revenue, FY2024, twelve months to 2024-12-31$482.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure564Revenue, FY2025, twelve months to 2025-12-31$564.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure
Gross margin%75.6%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $353.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-29, accession 0000950170-24-023150.Revenue: $467.4m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-29, accession 0000950170-24-023150.Report this figure76.7%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $345.9m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-27, accession 0000950170-25-029137.Revenue: $450.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-27, accession 0000950170-25-029137.Report this figure75.4%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $326.7m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-27, accession 0000950170-25-029137.Revenue: $433.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure76.0%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $366.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-27, accession 0000950170-25-029137.Revenue: $482.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figurenot reported (Gross profit not reported)
Operating margin%15.5%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $72.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-29, accession 0000950170-24-023150.Revenue: $467.4m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-29, accession 0000950170-24-023150.Report this figure4.9%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $22.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-029137.Revenue: $450.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-27, accession 0000950170-25-029137.Report this figure2.9%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $12.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730.Revenue: $433.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure(0.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$1.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730.Revenue: $482.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure7.9%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $44.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730.Revenue: $564.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure
Net margin%20.2%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $94.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-29, accession 0000950170-24-023150.Revenue: $467.4m. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-29, accession 0000950170-24-023150.Report this figure3.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $15.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-029137.Revenue: $450.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-27, accession 0000950170-25-029137.Report this figure1.1%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $4.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730.Revenue: $433.1m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure0.2%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $861.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730.Revenue: $482.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure6.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $37.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076730.Revenue: $564.2m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure
Diluted EPS$ per share0.70Diluted EPS, FY2021, twelve months to 2021-12-31$0.70 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-29, accession 0000950170-24-023150.Report this figure0.12Diluted EPS, FY2022, twelve months to 2022-12-31$0.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0000950170-25-029137.Report this figure0.04Diluted EPS, FY2023, twelve months to 2023-12-31$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure(0.01)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure0.15Diluted EPS, FY2025, twelve months to 2025-12-31$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure
Free cash flow$m30.8Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $62.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-29, accession 0000950170-24-023150.Capital expenditure: $31.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-29, accession 0000950170-24-023150.Report this figure(9.0)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $24.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0000950170-25-029137.Capital expenditure: $33.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0000950170-25-029137.Report this figure6.6Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $30.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076730.Capital expenditure: $24.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure4.2Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $14.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076730.Capital expenditure: $10.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure(24.5)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076730.Capital expenditure: $14.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076730.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Organogenesis Holdings Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
MORGAN STANLEY2026-06-30$28.5m11,721,609Added+104,814
Soleus Capital Management, L.P.2026-06-30$24.6m10,140,951Added+55,000
BlackRock, Inc.2026-06-30$17.6m7,249,528Added+2,349,777
DIMENSIONAL FUND ADVISORS LP2026-06-30$7.4m3,050,297Added+159,291
AQR CAPITAL MANAGEMENT LLC2026-06-30$7.3m3,011,753Added+2,130,036
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$7.1m2,905,919Added+5,103
D. E. Shaw & Co., Inc.2026-06-30$7.0m2,888,313Added+590,339
Assenagon Asset Management S.A.2026-06-30$4.8m1,967,952Unchanged
Assenagon Asset Management S.A.2026-06-30$4.8m1,967,952Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$4.7m1,935,554Added+151,590

Recent filings

All 670 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Organogenesis Holdings Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0616:45 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001193125-26-338321
2026-08-0616:15 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-338049
2026-08-0616:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-338022
2026-06-1616:32 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results0001193125-26-272710
2026-05-0716:16 ET10-QQuarterly reportPeriod 2026-03-310001661181-26-000008
2026-05-0716:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001661181-26-000007
2026-04-3016:17 ETDEF 14AProxy statementPeriod 2026-06-150001193125-26-197357
2026-02-2616:15 ET10-KAnnual reportPeriod 2025-12-310001193125-26-076730
2026-02-2616:09 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-076595
2026-02-2317:02 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-064270

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1661181
Tickers
ORGO
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer
Former names
Avista Healthcare Public Acquisition Corp. (to 2018-12-10)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.